


Laboratory Medicine in the Era of Disruptive Technology

## LMCE 2017 & KSLM 58th Annual Meeting

October 18-20, 2017 Grand Walkerhill Seoul, Korea www.lmce-kslm.org

## **Biois Co., Ltd.**

## Product Highlights Service (Display)



Advanced molecular diagnostics company focused on **precision medicine.** 



PGxOne<sup>™</sup> Plus Pharmacogenomics Testing to Predict a Patient's Drug Response

Cardiovascular Test Portfolio Risk Assessment, Disease Diagnosis and Treatment for Cardiovascular Diseases

Oncology Test Portfolio Tumor Profiling to Guide Selection of Targeted Therapies

To learn more about product portfolio visit admerahealth.com/products Biois Co., Ltd. is pleased to introduce the advanced genomic technology of admera health Inc. Admera Health's excellent Pharmacogenomics Test Service available Panel is now to Korean Pharmacogenomics researchers, clinicians, and reagents developers for anticancer drug response and companion diagnostics. Non-invasive cancer tests are designed for early disease detection, treatment guidance, treatment response monitoring, and disease recurrence monitoring. Admera Health is developing multiple non-invasive cancer tests to reduce the need for biopsy collection and other invasive sample collection from patients. Our targeted enrichment system detects tumor DNA from blood urine with exceptionally high or sensitivity specificity. eliminating and timeconsuming steps seen with most liquid biopsy analytic methods, enabling rapid turn-around of clinically actionable results to treating physicians. For more information about the Pharmacogenomics test service. Please contact marketing the department of Biois Co., Ltd. Thank you.

